Abstract
Inhalation therapy is one of the oldest approaches to the therapy of diseases of the respiratory tract. It is well recognised today that the most effective and safe means of treating the lungs is to deliver drugs directly to the airways. Surprisingly, the delivery of therapeutic aerosols has a rich history dating back more than 2,000 years to Ayurvedic medicine in India, but in many respects, the introduction of the first pressurised metered-dose inhaler (pMDI) in 1956 marked the beginning of the modern pharmaceutical aerosol industry. The pMDI was the first truly portable and convenient inhaler that effectively delivered drug to the lung and quickly gained widespread acceptance. Since 1956, the pharmaceutical aerosol industry has experienced dramatic growth. The signing of the Montreal Protocol in 1987 to reduce the use of CFCs as propellants for aerosols led to a surge in innovation that resulted in the diversification of inhaler technologies with significantly enhanced delivery efficiency, including modern pMDIs, dry powder inhalers and nebuliser systems. There is also great interest in tailoring particle size to deliver drugs to treat specific areas of the respiratory tract. One challenge that has been present since antiquity still exists, however, and that is ensuring that the patient has access to the medication and understands how to use it effectively. In this article, we will provide a summary of therapeutic aerosol delivery systems from ancient times to the present along with a look to the future.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Azouz W, Chrystyn H (2012) Clarifying the dilemmas about inhalation techniques for dry powder inhalers: integrating science with clinical practice. Prim Care Respir J 21:208–213
Boe J, Dennis JH, O’Driscoll BR et al (2001) European Respiratory Society guidelines on the use of nebulizers. Eur Respir J 18:228–242
Bonini M, Usmani OS (2018) Novel methods for device and adherence monitoring in asthma. Curr Opin Pulm Med 24:63–69
Buttini F, Miozzi M, Balducci AG, Royall PG, Brambilla G, Colombo P, Bettini R, Forbes B (2014) Differences in physical chemistry and dissolution rate of solid particle aerosols from solution pressurised inhalers. Int J Pharm 465(1–2):42–51
Buttini F, Rozou S, Rossi A, Zoumpliou V, Rekkas DM (2018a) The application of quality by design framework in the pharmaceutical development of dry powder inhalers. Eur J Pharm Sci 113:64–76
Buttini F, Balducci AG, Colombo G, Sonvico F, Montanari S, Pisi G, Rossi A, Colombo P, Bettini R (2018b) Dose administration maneuvers and patient care in tobramycin dry powder inhalation therapy. Int J Pharm 548:182–191
Chan AHY, Stewart AW, Harrison J et al (2015) The effect of an electronic monitoring device with audiovisual reminder function on adherence to inhaled corticosteroids and school attendance in children with asthma: a randomised controlled trial. Lancet Respir Med 3:210–219
Chrystyn H (2001) Methods to identify drug deposition in the lungs following inhalation. Br J Clin Pharmacol 51:289–299
Dalby R, Spallek M, Voshaar T (2004) A review of the development of Respimat Soft Mist Inhaler. Int J Pharm 283:1–9
De Boer AH, Hagedoorn P, Hoppentocht M, Buttini F, Grasmeijer F, Frijlink HW (2017) Dry powder inhalation: past, present and future. Expert Opin Drug Deliv 14(4):499–512
Dhand R (2002) Nebulisers that use a vibrating mesh or plate with multiple apertures to generate aerosol. Respir Care 47:1406–1416
Dolovich MB (2002) Assessing nebulizer performance. Respir Care 47:1290–1301
Doty A, Schroeder J, Vang K et al (2018) Drug delivery from an innovative LAMA/LABA co-suspension delivery technology fixed-dose combination MDI: evidence of consistency, robustness, and reliability. AAPS PharmSciTech 19:837–844
Ferguson GT, Hickey AJ, Dwivedi S (2018) Co-suspension delivery technology in pressurized metered-dose inhalers for multi-drug dosing in the treatment of respiratory diseases. Respir Med 134:16–23
Fleming J, Bailey DL, Chan H-K, Conway J, Kuehl PJ, Laube BL et al (2012) Standardization of techniques for using single-photon emission computed tomography (SPECT) for aerosol deposition assessment of orally inhaled products. J Aerosol Med Pulm Drug Deliv 25(Suppl 1):S29–S51
Foster JM, Reddel HK, Usherwood T et al (2017) Patient-perceived acceptability and behaviour change benefits of inhaler reminders and adherence feedback: a qualitative study. Respir Med 129:39–45
Ganderton D, Lewis D, Davies R, Meakin B, Brambilla G, Church T (2002) Modulite: a means of designing the aerosols generated by pressurized metered dose inhalers. Respir Med 96(Suppl D):S3–S8
Hoppentocht M, Akkerman OW, Hagedoorn P, Frijlink HW, De Boer AH (2015) The Cyclops for pulmonary delivery of aminoglycosides; a new member of the Twincer™ family. Eur J Pharm Biopharm 90:8–15
Iwanaga T, Tohda Y, Nakamura S, Suga Y (2019) The Respimat® soft mist inhaler: implications of drug delivery characteristics for patients. Clin Drug Investig. https://doi.org/10.1007/s40261-019-00835-z
Kikidis D, Konstantinos V, Tzovaras D et al (2016) The digital asthma patient: the history and future of inhaler based health monitoring devices. J Aerosol Med Pulm Drug Deliv 29:219–232
Laube BL, Janssens HM, de Jongh FH, Devadason SG, Dhand R, Diot P, Everard ML, Horvath I, Navalesi P, Voshaar T, Chrystyn H, European Respiratory Society; International Society for Aerosols in Medicine (2011) What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J 37:1308–1331
Lavorini F (2014) Inhaled drug delivery in the hands of the patient. J Aerosol Med Pulm Drug Deliv 27:414–418
Lavorini F, Fontana GA (2009) Targeting drugs to the airways: the role of spacer devices. Expert Opin Drug Deliv 6:91–102
Lavorini F, Corrigan CJ, Barnes PJ, Dekhuijzen PR, Levy ML, Pedersen S, Roche N, Vincken W, Crompton GK (2011) Retail sales of inhalation devices in European countries: so much for a global policy. Respir Med 105:1099–1103
Lavorini F, Fontana GA, Usmani OS (2014) New inhaler devices – the good, the bad and the ugly. Respiration 88:3–15
Lavorini F, Mannini C, Chellini E, Fontana GA (2016) Optimising inhaled pharmacotherapy for elderly patients with chronic obstructive pulmonary disease: the importance of delivery devices. Drugs Aging 33:461–473
Lavorini F, Pedersen S, Usmani OS (2017) Dilemmas, confusion, and misconceptions related to small airways directed therapy. Chest 151:1345–1355
Levy ML, Carroll W, Izquierdo Alonso JL, Keller C, Lavorini F, Lehtimäki L (2019) Adv Ther. https://doi.org/10.1007/s12325-019-01066-6
Molimard M, Raherison C, Lignot S, Balestra A, Lamarque S, Chartier A, Droz-Perroteau C, Lassalle R, Moore N, Girodet PO (2017) Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients. Eur Respir J 49. pii: 1601794
Morton RW, Elphick HE, Rigby AS et al (2017) STAAR: a randomised controlled trial of electronic adherence monitoring with reminder alarms and feedback to improve clinical outcomes for children with asthma. Thorax 72:347
Mudge J (1778) A radical and expeditious cure for a recent Catarrhous cough, 2nd edn. E. Allen, London, pp 131–147
Newman SP, Pitcairn GR, Hirst PH, Rankin L (2003) Radionuclide imaging technologies and their use in evaluating asthma drug deposition in the lungs. Adv Drug Deliv Rev 55:851–867
Newman S, Bennett WD, Biddiscombe M, Devadason SG, Dolovich MB, Fleming J et al (2012) Standardization of techniques for using planar (2D) imaging for aerosol deposition assessment of orally inhaled products. J Aerosol Med Pulm Drug Deliv 25(Suppl 1):S10–S28
O’Callaghan C, Barry PW (1997) The science of nebulised drug delivery. Thorax 52(Suppl 2):S31–S44
Price DB, Román-Rodríguez M, McQueen RB, Bosnic-Anticevich S, Carter V, Gruffydd-Jones K, Haughney J, Henrichsen S, Hutton C, Infantino A, Lavorini F, Law LM, Lisspers K, Papi A, Ryan D, Ställberg B, van der Molen T, Chrystyn H (2017) Inhaler errors in the CRITIKAL study: type, frequency, and association with asthma outcomes. J Allergy Clin Immunol Pract 5:1071–1081
Roche N, Dekhuijzen PNR (2016) The evolution of pressurized metered-dose inhalers from early to modern devices. J Aerosol Med Pulm Drug Deliv 29:1–17
Rogueda P, Traini D (2016) The future of inhalers: how can we improve drug delivery in asthma and COPD? Expert Rev Respir Med 10:1041–1044
Sanders M (2007) Inhalation therapy: an historical review. Prim Care Respir J 16:71–81
Sibum I, Hagedoorn P, de Boer AH, Frijlink HW, Grasmeijer F (2018) Challenges for pulmonary delivery of high powder doses. Int J Pharm 548:325–336
Skaria S, Smaldone GC (2010) Omron NE U22: comparison between vibrating mesh and jet nebulizer. J Aerosol Med Pulm Drug Deliv 23:173–180
Smaldone GC, Solomita M (2009) Predicting in vivo deposition in vitro. J Aerosol Med Pulm Drug Deliv 22:9–10
Stein SW, Thiel CG (2017) The history of therapeutic aerosols: a chronological review. J Aerosol Med Pulm Drug Deliv 30:20–41
Taylor G, Warren S, Orevillo C et al (2016) Pulmonary deposition of a novel LAMA/LABA co-suspension technology glycopyrronium/formoterol (GFF) MDI in healthy subjects. Eur Respir J 48:OA4834
Ziegler J, Wacthel H (2005) Comparison of cascade impactor and laser diffraction for particle size. J Aerosol Med 18:311–324
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Lavorini, F., Buttini, F., Usmani, O.S. (2019). 100 Years of Drug Delivery to the Lungs. In: Barrett, J., Page, C., Michel, M. (eds) Concepts and Principles of Pharmacology. Handbook of Experimental Pharmacology, vol 260. Springer, Cham. https://doi.org/10.1007/164_2019_335
Download citation
DOI: https://doi.org/10.1007/164_2019_335
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-35361-2
Online ISBN: 978-3-030-35362-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)